Mr. Roderick Matheson reports

MARVEL BIOSCIENCES RECEIVES NOTICE OF ALLOWANCE FOR AUSTRALIAN PATENT APPLICATION COVERING COMPOSITION OF MATTER FOR ITS LEAD THERAPEUTIC CANDIDATE MB-204

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., have noted the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026. The patent is expected to be granted shortly after Aug. 28, 2026.

The Australian notice of allowance further strengthens Marvel's global composition-of-matter patent portfolio for MB-204, reinforcing the company's intellectual property position as it advances into phase I clinical development following positive preclinical efficacy and toxicology results. Such includes recent preclinical studies in Rett syndrome models that demonstrated that MB-204 significantly outperformed the approved therapy trofinetide across multiple efficacy end points and produced sustained therapeutic benefits that persisted after treatment cessation, suggesting the potential for disease-modifying effects. Broadening patent protection across key pharmaceutical markets enhances the asset's commercial value by extending market exclusivity, reducing competitive risk, and increasing its attractiveness for potential licensing, partnering and strategic investment opportunities.

"We are continuing to extend our composition of matter patent protection of MB-204 to all major markets," commented Marvel chief executive officer Rod Matheson. "And we continue to look forward to receiving similar rulings for the other jurisdictions. We have also recently filed for patents on a novel liquid-based formulation of MB-204 which should help lengthen the lifetime of our patent estate."

MB-204 is a novel fluorinated analogue of the approved adenosine A2a receptor antagonist Istradefylline which is used for the treatment of Parkinson's Disease. MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, and has shown excellent preclinical efficacy studies in depression and multiple models of autism including Rett Syndrome. The compound is currently being tested in Fragile X models. Currently, around one in 36 children at age eight have been diagnosed with autism spectrum disorder which underscores the urgency for new agents.

The patent advancement follows a series of significant achievements in 2026, including the granting of United States and Japanese composition-of-matter patents for MB-204, the selection of Novotech as the company's contract research organization for its planned phase I clinical trial, the securing of non-dilutive funding support from Alberta Innovates, strategic investment participation from 5 Horizons Ventures and the development of novel pediatric-friendly liquid formulations that may further expand the company's intellectual property estate. Collectively, these achievements continue to validate Marvel's scientific platform, strengthen its credibility within the biotechnology sector and support the company's transition from a preclinical organization to a clinical-stage drug development company.

About Marvel Biosciences Corp.

Marvel Biosciences, through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. The company's lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market. Research shows that blocking the A2A receptor may help treat conditions such as autism, depression and Alzheimer's disease. Marvel is also exploring MB-204's potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments.

We seek Safe Harbor.